Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

Author： Halabi Susan Rini Brian I. Escudier Bernard Stadler Walter M. Small Eric J.

E-ISSN： 1097-0142|121|11|1906-1906

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.11, 2015-06, pp. : 1906-1906

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Reply to progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

By Becker Andreas Eichelberg Christian Sun Maxine

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1906-1907

Blackwell Publishing

Access to resources Recommend Favorite

HIV-1 immunogen does not appear to improve HIV progression-free survival

Inpharma, Vol. 1, Iss. 1263, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Missing Data and Censoring in the Analysis of Progression-Free Survival in Oncology Clinical Trials

By Denne J. S. Stone A. M. Bailey-Iacona R. Chen T.-T.

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 5, 2013-09 ,pp. : 951-970

Taylor & Francis Ltd

Access to resources Recommend Favorite

Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates

By Lipton Allan

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 5, 2011-04 ,pp. : 749-762

Informa Healthcare

Access to resources Recommend Favorite

A Review of Statistical Issues with Progression-Free Survival as an Interval-Censored Time-to-Event Endpoint

By Sun Xing Li Xiaoyun Chen Cong Song Yang

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 5, 2013-09 ,pp. : 986-1003

Taylor & Francis Ltd

Access to resources Recommend Favorite